Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
出版年份 2013 全文链接
标题
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 35, Pages 4453-4461
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2013-11-13
DOI
10.1200/jco.2013.51.0826
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
- (2015) Hayato Fujita et al. NEOPLASIA
- Gemcitabine elaidate
- (2014) B. Venugopal et al. DRUGS OF THE FUTURE
- Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
- (2012) Douglas G Altman et al. BMC Medicine
- Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
- (2012) Raphaël Maréchal et al. GASTROENTEROLOGY
- Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection
- (2011) Naru Kondo et al. ANNALS OF SURGICAL ONCOLOGY
- Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy
- (2011) Soichiro Morinaga et al. ANNALS OF SURGICAL ONCOLOGY
- Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
- (2011) Auke D. Adema et al. INVESTIGATIONAL NEW DRUGS
- Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy
- (2011) Yasuhiro Murata et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Stromal biology and therapy in pancreatic cancer
- (2010) A. Neesse et al. GUT
- Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
- (2010) Andries M. Bergman et al. INVESTIGATIONAL NEW DRUGS
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- (2009) R. Marechal et al. CLINICAL CANCER RESEARCH
- Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
- (2009) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma
- (2009) H Akita et al. ONCOGENE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
- (2008) William F. Regine et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More